The exact effect of AR expression on TNAC has not been elucidated, together with the question of whether anti-AR therapy can be applied in TNAC patients, whereas in triple-negative breast cancers (TNBC) of nonapocrine subtype, the expression of AR and its consequent effects are well documented. This evidence concerns the gene AR and triple-negative breast carcinoma.